本文選題：慢性阻塞性肺疾病 + 蘇黃止咳膠囊��； 參考：《遼寧中醫(yī)雜志》2017年06期

【摘要】：目的:探討蘇黃止咳膠囊治療慢性阻塞性肺疾病急性發(fā)展期的臨床療效以及長(zhǎng)期隨訪結(jié)果。方法:選取2014年1月—2015年6月來(lái)本院治療的107例老年慢阻肺患者為研究對(duì)象,隨機(jī)分為治療組和對(duì)照組,其中治療組53例,對(duì)照組54例。對(duì)照組患者給予常規(guī)治療,治療組患者在常規(guī)治療的基礎(chǔ)上,給予每天口服蘇黃止咳膠囊,3粒/次,3次/d,4周為1個(gè)療程。在療程結(jié)束后,進(jìn)行12個(gè)月以上的隨訪觀察。結(jié)果:隨訪期間,治療組與對(duì)照組比較,急性加重次數(shù)和再入院率明顯降低(P0.01);治療組的第一秒用力呼氣量占預(yù)計(jì)值百分比(FEV1)、第一秒用力呼氣量/用力肺活量(FEV1/FVC)均明顯升高,殘氣量(RV)、殘氣與肺總量比值(RV/TLC)均明顯降低,與治療前和對(duì)照組比較,差異均具有統(tǒng)計(jì)學(xué)意義(P0.05);另外,治療組的生存質(zhì)量評(píng)估表得分明顯降低,6 min步行距離明顯提高,與治療前和對(duì)照組相比較,差異均具有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:蘇黃止咳膠囊口服可以改善慢性阻塞性肺病患者的肺功能,提高生存質(zhì)量,減少慢性阻塞性肺病急性加重和再入院次數(shù)。
[Abstract]:Objective: to investigate the clinical effect and long-term follow-up of Suhuang Zhike capsule in the treatment of chronic obstructive pulmonary disease (COPD). Methods: 107 elderly patients with COPD treated in our hospital from January 2014 to June 2015 were randomly divided into treatment group (53 cases) and control group (54 cases). The patients in the control group were given routine treatment, and the patients in the treatment group were given three capsules of Suhuang Zhike capsule every day for 4 weeks as a course of treatment. At the end of the course of treatment, more than 12 months of follow-up observation. Results: during the follow-up period, the times of acute exacerbation and readmission rate in the treatment group were significantly lower than those in the control group, and the percentage of forced expiratory volume in the first second and FEV1 / FEV1 / FEV1 / FEV 1 / FVC in the treatment group were significantly higher than those in the control group, and the first second forced expiratory volume / forced vital capacity and FEV 1 / FVC were significantly higher in the treatment group than in the control group. The RV / TLC ratio and the ratio of residual gas to lung volume were significantly decreased, compared with those before treatment and control group, the difference was statistically significant (P 0.05), in addition, the score of QOL in the treatment group was significantly lower than that in the control group, and the walking distance of 6 min in the treatment group was significantly lower than that in the control group, and the score of RV / TLC in the treatment group was significantly lower than that in the control group. The difference was statistically significant compared with that before treatment and control group (P 0.05). Conclusion: Su Huang Zhike capsule can improve pulmonary function, improve quality of life and reduce acute exacerbation and readmission of chronic obstructive pulmonary disease.
【作者單位】： 天津市濱海新區(qū)大港醫(yī)院;
【分類(lèi)號(hào)】：R563.9

【相似文獻(xiàn)】

相關(guān)期刊論文 前3條

1 歐陽(yáng)曉平;吳峰;顧揚(yáng);陶玉堅(jiān);黃玉民;;沙美特羅替卡松聯(lián)合蘇黃止咳膠囊治療咳嗽變異性哮喘療效觀察[J];臨床肺科雜志;2013年02期

2 韓淑慧;代育中;范愛(ài)紅;;蘇黃止咳膠囊聯(lián)合酮替芬治療咳嗽變異性哮喘的療效及安全性評(píng)估[J];當(dāng)代醫(yī)學(xué);2014年04期

3 ;[J];;年期

相關(guān)碩士學(xué)位論文 前1條

1 李楠楠;蘇黃止咳膠囊治療輕、中度支氣管哮喘的臨床研究[D];泰山醫(yī)學(xué)院;2013年

，

本文編號(hào)：1798598